Early standardized global review for people with axial spondyloarthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a pragmatic, cluster-randomized, controlled, open-label study lasting one year that compares centers delivering an early standardized global review to centers providing usual care. Centers are randomized (not individual patients), and control centers are not informed about the intervention details to limit bias. The intervention includes assessment of disease domains and patient education, and the primary outcome is change in the SPAKE knowledge questionnaire between baseline and 12 months. Eligible participants are adults diagnosed with axSpA within the prior 12 months who can complete study activities, while those who already received a dedicated education/global evaluation or who have conditions limiting understanding or adherence are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (but age \<80years) with a diagnosis of axial spondyloarthritis determined by the treating rheumatologist within the 12 months preceding the baseline visit, who have completed the informed consent and have the ability to complete all study activities.

Exclusion Criteria:

* Patients who have already received a specific (or plan to receive in the coming 12 months) and dedicated program/global evaluation including education on the disease or treatments.
* Patients with any physical or mental condition that may affect understanding of the intervention or adherence to treatment (e.g. major depression or substance/alcohol use - might have impact on the outcomes of interest in the study).

Where it's running

• CHU Caen
  Caen, France Recruiting
• AP-HP - Hôpital Henri Mondor
  Créteil, France Recruiting
• AP-HP - Hôpital Bicêtre
  Le Kremlin-Bicêtre, France Recruiting
• AP-HP - Hôpital Cochin
  Paris, France Recruiting
• AP-HP - Hôpital La Pitié Salpétrière
  Paris, France Recruiting
• AP-HP - Hôpital Saint Antoine
  Paris, France Recruiting

Study contacts

• Study coordinator: Anna Molto
• Email: anna.molto@aphp.fr
• Phone: +33158412576

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FAPI‑74 PET/CT versus FDG PET/CT for inflammation in FUO, IgG4‑RD, and axial spondyloarthritis

  This project will test whether [18F]-AlF-FAPI-74 PET/CT finds inflammation more accurately than standard [18F]-FDG PET/CT in people with fever of unknown origin, IgG4‑related disease, or axial spondyloarthritis.

  Recruiting Phase 2/3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07535554

• Comparing five advanced treatments for axial spondyloarthritis and psoriatic arthritis

  This project will see how well bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor work for adults with axSpA or PsA who have just started one of these medicines, using medical records and patient surveys.

  Recruiting Adelphi Real World · Bath, Somerset · NCT07166315

• Personalized lab test to predict the best treatment for rheumatic diseases

  This project tests a lab-based cell assay to see if it can predict which DMARD will work best for adults with autoimmune rheumatic diseases such as RA, PsA, axSpA, and GCA.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT07150000

• Evaluating movement recommendations for patients with axial spondyloarthritis using smartwatches

  This study is testing how using smartwatches to track movement can help people with axial spondyloarthritis find better ways to stay active and manage their symptoms.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT06807853

• Validation of the 2025 Axial Spondyloarthritis Classification Criteria in Chinese patients

  This study tests whether the 2025 ASAS-SPARTAN criteria correctly classify axial spondyloarthritis in adults with chronic back pain in China.

  Recruiting Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07724847

• Lowering JAK inhibitor doses in people with RA, PsA, or axSpA who are in low disease activity or remission

  This study will test whether carefully lowering the dose of Janus kinase inhibitors keeps disease control as well as staying on the same dose in people with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who are in remission or have low disease activity.

  Recruiting Phase 4 Sint Maartenskliniek · Nijmegen, Gelderland and 6 other locations · NCT07160231

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.